Extended Data Fig. 3: In vivo efficacy, safety and TIL analysis in B16F10-OVA and CT26 tumors.

(a–n) B16F10-OVA tumor study related to Fig. 1f–l. (n = 7 mice per group. But n = 6 (hIgG), n = 7 (IL-2^wt) and n = 5 (IL-2^nα) mice were analyzed for (b–n), as data was not available due to tumor ulceration (n = 1 in hIgG) and premature deaths (n = 2 in IL-2^nα treated group)). (a) Individual tumor growth curves. (n = 7 mice). (b, c) Tumor weight and wet lung weight measured at the end of the study. (d) Intratumoral CD8 to T_reg ratio in each treatment group. (e) Representative contour plots of PD-1 versus CD39 in CD8⁺TILs (black) and dot plots showing OVA-tetramer⁺CD8⁺TILs (red) after treatment. (f) Frequency of CD25⁺% and CD25 expression levels (MFI) in CD39^- or CD39⁺ CD8⁺TIL subsets. (g) Frequency (in CD45⁺ cells) and absolute cell numbers of OVA-tetramer⁺CD8⁺TILs in tumors. (h) Frequency (in CD45⁺ cells) and absolute cell numbers of Ki67⁺OVA-tetramer⁺ CD8⁺TILs in tumors. (i-j) Frequency (in CD45⁺ cells) and absolute cell numbers of CD8⁺ and Ki67⁺CD8⁺ TILs in tumors. (k-l) Frequency (in CD45⁺ cells) and absolute cell numbers of CD4⁺ and Ki67⁺CD4⁺ TILs in tumors. (m-n) Frequency (in CD45⁺ cells) and absolute cell numbers of intratumoral T_reg and Ki67⁺T_reg cells. (o–r) Efficacy and safety evaluation in CT26 tumor model. Average tumor volume changes (o), body weight changes (p), individual tumor growth curves (q) and wet lung weight (r) were shown. n = 7 mice per group. One mouse died prematurely in IL-2^nα group, so only n = 6 data points were shown in IL-2^nα group in (r). Mean + s.e.m. is presented, and p-values calculated using one-way ANOVA for bar graphs, two-way ANOVA for tumor growth curves and body weight changes, and two-sided paired t-test for symbols & lines plots.

Source data